Financings in Brief: Neoprobe
This article was originally published in The Gray Sheet
Executive SummaryNeoprobe: Adopts pre-emptive shareholder rights plan designed to protect the interests of its shareholders in the event of a "coercive or unfair takeover" attempt. Under the plan, one right will be distributed for each share of common stock on Aug. 28. "Each right entitles stockholders to purchase one-hundredth of a share of a special series of preferred stock at an exercise price of $35," the firm states. The exercise price could be modified "if someone acquires or tenders for 15% or more of the company's common stock." Neoprobe is developing its RIGS system for diagnosis and treatment of cancer ("The Gray Sheet" April 10, In Brief)...
You may also be interested in...
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.